Tela Bio, INC Form 4 insider transactions

William J. Plovanic, a Director of TELA Bio, Inc., received 20,930 shares of common stock on July 15, 2026.

Joseph H Capper, a Director of TELA Bio, Inc., received 6,227 shares of common stock on July 15, 2026.

Director Betty Jo Rocchio acquired 11,675 restricted stock units and 17,335 stock options as part of annual equity compensation.

Director Joseph Capper was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

Director William J. Plovanic acquired 11,675 restricted stock units and 17,335 stock options as part of an annual equity grant.

Director Guido Neels was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

Director Paul Thomas was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

Director Guy P. Nohra was granted restricted stock units and stock options as part of TELA Bio's equity incentive plan.

TELA Bio's CEO, Antony Koblish, acquired significant equity awards and simultaneously sold shares to cover tax liabilities from RSU vesting.

TELA Bio's Chief Business Officer, Gregory A. Firestone, reported significant equity awards including 37,000 restricted stock units and 55,000 stock options, alongside routine tax-related share dispositions.

TELA Bio's Chief Technology Officer, Paul Talmo, reported the acquisition of restricted stock units and stock options, alongside shares withheld for tax obligations.

TELA Bio's COO and CFO, Roberto Cuca, reported the acquisition of 57,000 restricted stock units and 85,000 stock options, alongside tax-related share dispositions.

TELA Bio's President, Jeffrey Blizard, acquired 86,000 restricted stock units and 127,000 stock options, signaling long-term commitment.

TELA Bio's Chief Accounting Officer, Megan Smeykal, received a grant of 32,850 restricted stock units, with subsequent share disposals for tax obligations.

EW Healthcare Partners Funds acquired 3.6 million shares of TELA Bio common stock in a direct offering, increasing their total beneficial ownership to over 7.7 million shares.

TELA Bio, Inc. Director William J. Plovanic reported the acquisition of 11,925 restricted stock units and options to purchase 17,550 shares of common stock.

TELA Bio, Inc. Director Betty Jo Rocchio received grants of restricted stock units and stock options as part of her compensation.

TELA Bio's Chief Commercial Officer, Gregory A. Firestone, reported a disposition of shares for tax withholding purposes, while also increasing overall beneficial ownership.

TELA Bio, Inc. has reported that its President, Jeffrey Blizard, was granted 104,800 restricted stock units and 154,100 stock options as part of his compensation, aligning his interests with long-term company performance.

TELA Bio, Inc. Director Douglas G. Evans was granted 7,950 restricted stock units and options to purchase 11,700 shares of common stock, aligning his interests with shareholders.

TELA Bio, Inc. Director Federica F. O'Brien was granted 7,950 restricted stock units and 11,700 stock options as part of her compensation, aligning her interests with shareholders.

TELA Bio, Inc. Director Kurt Azarbarzin was granted 7,950 restricted stock units and 11,700 stock options as part of his compensation, aligning his interests with shareholders.

TELA Bio, Inc. Director Jeffrey Blizard was granted 7,950 restricted stock units and options to purchase 11,700 shares of common stock on May 28, 2025, as part of his compensation package.

TELA Bio, Inc. Director Vincent J. Burgess was granted 7,950 restricted stock units and 11,700 stock options, aligning his compensation with the company's performance and shareholder interests.

TELA Bio, Inc. Director Lisa N. Colleran was granted 7,950 restricted stock units and options to purchase 11,700 shares of common stock, aligning her interests with shareholders.

Chief Technology Officer Paul Talmo of Tela Bio, Inc. reports a transaction involving common stock to cover withholding taxes.

Megan Smeykal, Chief Accounting Officer and Controller of TELA Bio, Inc., reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.

CEO Antony Koblish reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Gregory A. Firestone, Chief Commercial Officer of TELA Bio, Inc., disposed of 119 common stock shares to cover withholding taxes upon the vesting of restricted stock units on March 31, 2025.

Roberto Cuca, COO and CFO of Tela Bio, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of shares to cover withholding taxes.